Non-alcoholic fatty liver disease and type 2 diabetes mellitus a prospective observational study in coastal region of Andhra Pradesh
DOI:
https://doi.org/10.18203/2349-3933.ijam20212401Keywords:
Non-alcoholic fatty liver disease, Type 2 diabetes mellitus, Metabolic parametersAbstract
Background: Non alcoholic fatty liver is the most common chronic liver disease in many parts of world including India. It is strongly associated with obesity, overweight and insulin resistance. Type 2 diabetes is common condition and it regularly coexists with NAFLD. We designed to study non alcoholic fatty liver among type 2 diabetes mellitus among people of costal Andhra Pradesh and impact of this disease on metabolic profile of patients.
Methods: As per selection criteria 160 patients with type 2 diabetes mellitus were enrolled for this study. A detailed history of patients was taken regarding demography of patients, duration of diabetes mellitus, drug history, alcohol consumption and symptoms of hepatic disorder.
Results: Out of that 86 (53.75%) patients were diagnosed to be non alcoholic fatty liver disease. There was significant difference between with NAFLD and without NAFLD groups regarding FPG (mg/dl) (144.12±10.54 vs. 122.48±11.67) (p=0.0001). AST/ALT ratio was significantly lower in patients with NAFLD then without NAFLD groups (0.81±0.19 vs. 1.16±0.31) (p=0.0001). Alkaline phosphotase (IU/l) was significantly higher in patients with NAFLD then without NAFLD groups (157.83±47.21 vs. 134.24±32.76) (p=0.0004).
Conclusions: In current study the prevalence of NAFLD was 53.75% among type 2 diabetes mellitus patients. There was female predominance in patients with NAFLD and T2DM but in non NAFLD with T2DM has male predominance. There was significant difference between with NAFLD and without NAFLD groups regarding BMI. Hepatic parameters like AST, ALT and Alkaline phosphotase was significantly higher and AST/ALT was significantly lower in patients with NAFLD then without NAFLD groups.
References
Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease?. BMJ. 2011;343:d3897.
Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016;65:1096-108.
Targher G, Byrne CD. Clinical review: Nonalcoholic fatty liver disease: A novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98:483-95.
Dharmalingam M, Yamasandhi PG. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J Endocrinol Metab. 2018;22(3):421-8.
Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29(1):113-9.
Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009;57: 205-10.
Tilg H, Moschen A, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32-42.
Amiri DAN, Koushki M, Motedayen M. Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2017;10(Suppl1):S1-7.
Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793-801.
Bhatt KN, Pranav V, Dipika Y, Dharmesh N, Radhika N, Arvind S. Prevalence of nonalcoholic fatty liver disease in type 2 diabetes mellitus and its relation with insulin resistance in South Gujarat Region. J Mahatma Gandhi Inst Med Sci. 2017;22:8.
Clark JM, Brancati FL, Diehl AM: The prevalence and aetiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960-7.
Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol. 2020; 6:9.
Xia MF, Bian H, Gao X. NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Front Pharmacol. 2019;10:877.
Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere BM, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57-63.
Arrese M. Nonalcoholic fatty liver disease: liver disease: an overlooked complication of diabetes mellitus. Nat Rev Endocrinol. 2000;6(12):660-1.
Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care. 2011;34(3):727-9.
Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734-43.
Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015;19(5):597-601.
